Avacta Group chief scientific officer, Dr Amrik Basran, will be presenting an update on the Affimer therapeutics programmes at the Protein and Antibody Engineering Summit which starts in Lisbon today.
Basran will present recent progress in the Affimer therapeutic programmes and will focus on PD-L1 immune checkpoint inhibitors and half life extension methods.
Basran will discuss new data concerning a range of Affimer proteins that bind to serum albumin, which can be used to form bispecifics to extend serum half-life.
The summit runs until 17 Nov.
Avacta also announced that chief executive Alastair Smith would be presenting at an investor evening hosted by Turner Pope Investments on 4 Dec. The event will be held in Mayfair, London W1, at 5 p.m.